AR and prostate cancer: The observed reductions in AR mRNA and protein levels in two PCa cell lines (Fig. 1) confirm the feasibility and therapeutic relevance of siRNA-LNPs for modulating the AR pathway, which is a key driver of prostate cancer progression (Heinlein and Chang, 2004).